|
Post by esstan2001 on Sept 8, 2016 9:51:57 GMT -5
To be on the same list as Apple, Facebook, Bank of America, etc. is just borderline comical I love it. You mean Mannkind, or BABAoriley? If you mean baba, well, now that IS comical.
|
|
|
Post by esstan2001 on Sept 8, 2016 9:48:48 GMT -5
To be on the same list as Apple, Facebook, Bank of America, etc. is just borderline comical I love it. True enough! And don't forget how high up on the list of shorted companies we've been. This stock has been a lightning rod for stock market gamblers and manipulators for years. Way out of proportion with our size. By the way, it also boasts an outsize share of message board posts! And baba- did you happen to notice that you are on the list too? ...Looks on balance like the markets are about 70/30 bullish on you. Who is willing to take this bet?
|
|
|
Post by esstan2001 on Aug 30, 2016 15:47:13 GMT -5
You laid out a very plausible case that gets the company through the hoop- it provides enough time to see whether Afrezza will leave a real mark on our world or will remain a nice but unremarkable niche product (all instincts point to the former).
|
|
|
Post by esstan2001 on Aug 30, 2016 8:33:15 GMT -5
This is a reply by Mike C. ....... in our hands and we will ensure we make Al Mann's vision a reality. Sorry prvs, I somehow,missed your post- you beat me to the punch :-)
|
|
|
Post by esstan2001 on Aug 30, 2016 8:05:47 GMT -5
Bottom line is that I think that management is doing a much better job of responding to shareholders in 2016 than they have in previous years.
Castagna responded to LFD's latest SeekingAlpha article. See the comment by castagna2011 dated '30 Aug 2016, 01:52 AM' at this link: seekingalpha.com/article/4002856-mannkind-curtain-drawn-microphone-placeManagement is on the ball. Mike's reply post needs to be seen. A real thing of beauty... castagna2011 Comments (1) |+ Follow |Send Message Dear Diogenes, Almost 70% of diabetics are not at goal, this is something we need to focus on. As you may or may not know over 200 people with diabetes a day get amputations and ~6 people with diabetes an hour start dialysis because they haven't been able to control their blood sugars for a long time (http://tinyurl.com/zvs...). Now that you understand we are talking about a real disease with real challenges, I would like to highlight some issues with your article: 1) When you want to compare sales rep impact, don't compare and apple to an orange. Your analysis looks at a rep who has been in a territory calling on a doctor for 9+ months and you are comparing to a time period when we didn't even have a sales force present post the ADA meeting and then attempting to make conclusions about their impact. I would suggest you see what the impact our reps have after 9 months of calling on their customers before you say they are ineffective or have an low ROI. 2) Our sales force started the first week of July, mid-year when many lunch appointments were already booked. I am very proud my team has been able to stop an almost 12 month decline in NRx in less than 4 weeks of being in the field and demonstrate growth in NRx during the month of August despite a Medicare/Medicaid challenge. Don't forget for every rep we had, Sanofi had ~7-10 reps in a territory,therefore their NRx per rep would even be less than ours and we are doing this a fraction of the cost and have been making an immediate impact. We have had almost 200 new trialists who wrote their first Afrezza Rx in the last 13 weeks and have had a significant number of sample and copay card requests via our website in the last 4 weeks. These are programs we stated were launching in August and most have only landed in our sales reps hands in the last 3 weeks. 3) I joined MannKind <5 months ago and I would ask you to find a company or team who launched a fully integrated commercial team, built distribution capabilities, managed a smooth inventory transition across 80 distribution centers with new NDCs and built a new marketing campaign along with all the field tools to go with a launch in <90 days. This has to be a record for any company in this industry. I have been doing this a long time and companies spend tens of millions of dollars, a lot more people and 12+ months of planning. 4) While ADA was important for us to meet thought leaders, build international relationships and showcase our new data, this was the foundation of information that is required for us to file for a label change. This is not information our field team can use immediately, so I wouldn't expect an impact from this. I wish more doctors had time to read and review our publications as well as the ADA data as they would then understand our brand and likely prescribe it for even more patients. 5) Please note the significant number of NRx that were previously generated in 2015 rarely converted to refills week after week. Our focus is on making sure patients start appropriately and stay on our product. The strategy between MannKind and Sanofi are completely different and while I understand generating NRx's are important, it is more important we keep patients on our product once we get them and that is a big focus of ours. Everyone understands the beauty of compounding growth versus single hits. Finally, regarding what Matt may or may not have said about the payor space is in the past. We have deep expertise in this area and are focused on removing barriers for patients to get access to our product. Afrezza has not had a price increase in 2 years, but many insurance companies still penalize patients by putting us on a higher copay/tier despite us holding the price of this product. We know the payor space well and unfortunately these things take time to make changes and I am confident we will share our value proposition with our payor colleagues and enhance access to Afrezza. However, at the current time we have created a reimbursement center to help patients get access to our product as efficiently as possible. It should also be noted that we have significant coverage for commercial plans, but Medicare is a challenge which is ironic because these are government insured patients/voters and the price increases in the insulin market are being paid for by all of us as taxpayers given this is the #1 expense category for payors and healthplans. We should be demanding Medicare open up access for Afrezza so that we can give patients another option that can help them control their disease. In the future, I hope you find time to write about why insurance companies and Medicare plans are restricting patients access to a product that hasn't taken price increase and in effect are driving up patients out of pocket costs as well as our tax bills and how this prevents patients from getting access to our brand as they attempt to get their disease under control. I joined this company because I know we will help patients and we serve an unmet need every single day. I get story after story of how our product changed the life of a person living with the disease, a spouse who got their husband back or parent who has more comfort that their college kid can control their disease without having their insulin pump attached to them. I recognize the financial situation of the company and the job of good leaders is to make the right short and long term decisions to grow and sustain. If anyone reacts to 1 week of NRx they are short sighted. This company has survived many doom and gloom reports all the way back to 2005. We finally have our brand FDA approved, in our hands and we will ensure we make Al Mann's vision a reality
|
|
|
Post by esstan2001 on Aug 25, 2016 19:14:08 GMT -5
Baba, believe it or not, Mankind Cares actually does care. My pharmacist actually asked me, who the heck are these Mankind Cares guys? It remains to be seen, if Endo's will be smart enough to utilize the services of Mankind Cares to help not only themselves, but also their patients in the pre- authorization process with the insurance companies. Hopefully in several month's NRx numbers could start to see the impact of this help. Spiro here, 2 boxes in the fridge and 2 more coming next month. Judging by the reaction of your pharmacist, Mike may have created a groundbreaking new model of operation that if scales well, could ultimately make the big difference we are all pining for.
|
|
|
Post by esstan2001 on Aug 25, 2016 12:56:25 GMT -5
Ok, it's time for Spiro to share his story. ....... ...... Spiro does not know what Mankind Cares did to convince his insurance company to cover Afrezza, but they damn sure got the job done. Spiro here, It sure seems that MNKD is getting it's act together Spiro, great story! And have you been back to the pharmacy, and if so, how did it go? If it went smoothly (not possible), you should email Matt and let him know about your experience. By any chance did the MannKind Care personnel have Indian accents? OK Baba, I want to know how you expect a Greek to differentiate between an Indian and Pakistani accent (or for that matter, Algonquin, Iroquois, Cherokee, Apache...) they are all Greek to me!
|
|
|
Post by esstan2001 on Aug 15, 2016 22:23:03 GMT -5
I prefer
...recommended dosing within 15 minutes after the start of the meal.
then something to the effect of
... Supplemental doses to cover [verbage describing slow to metabolize foods] as required
|
|
|
Post by esstan2001 on Aug 9, 2016 11:15:24 GMT -5
Depends too on whether you are looking at COGS to determine per unit margin, or a more general estimate of costs to company to achieve 'breakeven'. Based on Peppy's estimated numbers (or whatever 'public' data you can find you trust), you could guesstimate COGS (per unit) - and try to extrapolate/guesstimate based on SNY's number the margin through distribution. But this will not remotely give you breakeven. Even if you had #2 in that list above, there are still other expenses and overhead costs to factor in. I think I'm getting a headache. Most companies I usually look at provide some sort of guidance as to future losses/profits, revenues, expenses, etc. I take it that isn't a standard operating procedure with MNKD? It was clear from what Mike said that it is much too early to provide guidance on sales / revenues. This is a product launch, new team, new methodology, new targets, new marketing. We are in the 1st week to first month for the moving parts. No credible person would hazard a guess, and that is all it would be.
|
|
|
Post by esstan2001 on Aug 9, 2016 10:37:09 GMT -5
They will never disclose publicly what their cost to manufacture is; it also will vary based on fixed costs and volume produced. The best you can hope for is a reasonable long run estimate for analysis purposes.
|
|
|
Post by esstan2001 on Aug 8, 2016 16:46:03 GMT -5
just 1 question on the call-
this is off of Wall St's radar.
|
|
|
Post by esstan2001 on Aug 5, 2016 16:06:27 GMT -5
Today I had all my shares in the second of three Schwab accounts returned. and I used to think that weekends were just made for Michelob... they seem not to want to be short weekends. If it was any other Monday, I'd bet they'd just take the shares back. Maybe this one's different...
|
|
|
Post by esstan2001 on Aug 4, 2016 13:18:53 GMT -5
Please go back and look what Mnkd technology is based on and how rapid onset is crucial in such situations. You should probably ask why an insulin pill isn't available yet after all these years? Did you call Hakan yet? Let's be fair to mango and NOT jump to conclusions YET. YES, inhaled pulmonary delivery with rapid onset is crucial in some situations, like being discussed for Anaphylaxis; however, mango points out some interesting options. Perhaps they might work rapidly enough, or perhaps not, but I think that the other "off label" applications would have less of an issue with the same suggestions. Surely, MNKD's strategy is to use the regulatory framework in the most advantageous way possible after the drubbing it gave them last time. Regarding insulin in a pill, I think that the true genius of Al Mann was realizing that TIME MATTERS when everyone assumed long ago that it does not. That said, for basal insulin, a pill would be ideal to put an end to all injections. I don't see ORMP doing it well. I do see how Technosphere could do it well. If only the FDA was not such a PITA. ...and for the record, an Epi pill would have applications, but the link provided was not meant as a pill. I think the intent was still inhalation. Unigene, Tarsis(?) Emisphere, etc in collaborations with Novo, GSK, etc have all been working on an enteric coating for peptide delivery (Pth, calcitonin, insulin, GLP1, etc) through the gut. Successfully getting through there, and limiting dosing variability have kept the holy grail out of reach. Digestive trac delivery is fraught with variability. Someday, and it depends on the peptide / target treatment- but I do not think too soon.
|
|
|
Post by esstan2001 on Jul 18, 2016 16:55:29 GMT -5
I seem to remember posts discussing the possible deterioration of this over time. Can't remember if here or some clown on YMB inventing problems. While we need FDA approval in USA, I doubt MNKD, in the spirit of Al, would sell something not 100% viable and safe. Does anyone here have the professional expertise to evaluate the longevity of the P insulin in frozen storage? The company tests the insulin in storage on a regular basis (and maintains records in case of later FDA submission) to determine it's continued viability for use, per the 2015 Danbury factory tour.
|
|
|
Post by esstan2001 on Jul 11, 2016 22:29:12 GMT -5
signed.
|
|